Milestone: Creating Innovative Solutions Milestone Home
 
image thru microscope
Symposia Contact Home

CPSA Digest 2003

From Proteomics to the Pill:
New Initiatives in Proteomics, Drug Discovery, and Development

September 22-24, 2003

CPSA Digest 2003

Day 1: Proceedings | Plenary
Day 2: Proceedings
Day 3: Proceedings

CPSA 2003 Sponsors

CPSA Digest Archive
CPSA Digest 2000
CPSA Digest 2001
CPSA Digest 2002
CPSA Digest 2003 >>
CPSA Digest 2004


Day 3

WeOC1

A "Platform" for Research Informatics:
Capture, Catalog, View, Share and Re-Use

John Helfrich, NuGenesis Technologies


Pharmaceutical Data and Information Landscape
There are many specific tools for creating, storing, accessing and utilizing data and information within the spectrum of pharmaceutical drug development. These tools are used by different departments and functions across the entire timeline of development. This patchwork process has created many different software platforms for Information Technology to support. Additional value can be generated when data are collected into a data management platform.

Biopharmaceutical Data/Information Landscape diagram

In drug discovery there may be 5,000 compounds that are considered within a variety of therapeutic arenas. Over the next several years, a reasonable estimate is that 5-10 compounds reach the IND phase of development. Another multiple year process of clinical trials may yield only one or two marketable drugs. The path from 5,000 drugs to one drug yields a tremendous amount of data. Rather than focus on only the data from the one successful drug, the data from the 4,999 drugs that did not make it through the process yields valuable data from a bioinformatics perspective. These negative data provide interesting information on many aspects such as structure activity relationships. Toward the goal of reducing the timeframe for drug development, an in-silico predictive process may be developed from the data collected and used very early in development.

Pharmaceutical Industry Challenges
A goal from the perspective of an innovator pharmaceutical company is determining how to maintain double digit growth. The challenges to reach this goal are listed:

  • Accelerate the discovery process to reduce cycle time to IND from six years to three years
  • Increase the number of New Chemical Entities (NCE) that reach clinical trials from 1-2/year to 2-4/year
  • Reduce the "time-to-market" from 12-15 years to under 10 years
  • Reduce total drug discovery and development costs from ~$800M per drug to under $400M per drug
  • Insure a solid intellectual property and regulatory compliance position
Several approaches for using research informatics in drug development are presented within this session. First, a global perspective on analytical data management is shared (a strategic overview from an innovative company). Second, a focus on specific tools currently used for data management. Finally, an overview of a system developed for knowledge sharing and scientific knowledge management is presented.


Return to Proceedings »



overview | training | workshops | consulting | symposia | contact | home